v3.20.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jul. 31, 2020
Jul. 31, 2019
Operating activities    
Net loss $ (49,096) $ (77,866)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation and amortization 17,621 10,193
Amortization of intangible assets 207 285
Amortization of deferred contract acquisition costs 28,171 15,076
Non-cash operating lease cost 4,939 0
Change in fair value of redeemable convertible preferred stock warrant liability 0 6,022
Provision for bad debts (269) 22
Stock-based compensation expense 61,351 33,611
Gain on sale of debt securities, net (1,347) 0
Accretion (amortization) of marketable securities purchased at a discount 578 (960)
Non-cash interest expense 320 163
Changes in operating assets and liabilities    
Accounts receivable 16,020 (22,802)
Deferred contract acquisition costs (48,988) (27,788)
Prepaid expenses and other assets (1,953) (12,505)
Accounts payable 9,634 (5,897)
Accrued expenses and other current liabilities (8,112) (2,095)
Accrued payroll and benefits (711) 773
Operating lease liabilities 1,315 0
Deferred revenue 118,672 79,362
Other liabilities 5,250 (393)
Net cash provided by (used in) operating activities 153,602 (4,799)
Investing activities    
Purchases of property and equipment (30,334) (37,159)
Capitalized internal-use software (3,850) (3,310)
Purchase of strategic investments (1,000) 0
Purchases of marketable securities (84,904) (117,572)
Proceeds from sales of marketable securities 639,586 4,473
Maturities of marketable securities 91,605 123,314
Net cash provided by (used in) investing activities 611,103 (30,254)
Financing activities    
Proceeds from the issuance of common stock upon initial public offering, net of underwriting discounts 0 665,092
Payments of deferred offering costs 0 (4,080)
Proceeds from issuance of common stock upon exercise of stock options 16,601 8,526
Proceeds from the issuance of common stock upon exercise of early exercisable stock options 0 10,264
Proceeds from issuance of common stock under the employee stock purchase plan 17,284 0
Capital contributions from non-controlling interest holders 550 0
Net cash provided by financing activities 34,435 679,802
Effect of foreign exchange rates on cash and cash equivalents 796 (349)
Net increase in cash and cash equivalents 799,936 644,400
Cash and cash equivalents, beginning of period 264,798 88,408
Cash and cash equivalents, end of period 1,064,734 732,808
Supplemental disclosure of cash flow information:    
Interest paid 0 2
Income taxes paid, net of refunds received 663 413
Supplemental disclosure of non-cash investing and financing activities:    
Conversion of redeemable convertible preferred stock to common stock 0 659,207
Conversion of redeemable convertible preferred stock warrant liabilities reclassified to additional paid-in capital 0 10,559
Net increase (decrease) in deferred offering costs, accrued but not paid 0 (1,078)
Net increase (decrease) in property and equipment included in accounts payable and accrued expenses (1,020) 3,820
Vesting of early exercised stock options $ 1,722 $ 854